摘要
目的:研究马蹄金素衍生物的体外抗肿瘤活性。方法:采用MTT法检测3个马蹄金素衍生物对人肝癌细胞株HepG2和正常肝细胞L02细胞的生长增殖影响。结果:3个化合物对肝癌细胞株HepG2的细胞毒性IC50分别为51.59、29.51、6.37μg/mL,而对正常肝细胞L02细胞的细胞毒性IC50分别为247.0、191.6、60.6μg/mL。3个化合物在给药质量浓度≥10μg/mL时,对这两种细胞增殖影响差异具有统计学意义(P<0.05)。结论:3个化合物对正常肝细胞L02和肝癌细胞HepG2均有抑制作用,对L02细胞毒性较低,而对肝癌细胞HepG2具有较强的增殖抑制作用,并且呈现出剂量-效应关系。其中Y26对肝癌细胞HepG2的细胞毒性最高,IC50为6.37μg/mL。
Objective：To study anti-tumor activities of Matijing-Su derivatives in vitro. Methods： MTT assay was used to evaluate the inhibitive effect of three compounds on inhibited proliferation of normal human hepatocytes L02 and human hepatoma HepG2 cells in vitro. Results：The ICs0 values of these compounds towards H epG2 cells were 51.59,29.51,6.37 μg/mL respectively, and these towards L02 cells were 247.0,191.6,60.6 μg/mL separately. The difference of inhibition ratio of HepG2 cells and L02 cells was statistically significant when the drug concentration ≥10 μg/mL （P〈0.05）. Conclusion：It was found that these compounds showed obvious effects on inhibited proliferation of HepG2 cells, and had weak effects on inhibiting proliferation of L02 cells for 72 h. The results showed that these compounds displayed an inhibiting effect on the proliferation of HepG2 cells with a dose-effect rela- tionship. Compound Y26 （ICs0：6.37μg/mL） showed the most potency in vitro anti-tumor activity in the tested Compounds.
出处
《亚太传统医药》
2014年第5期16-18,共3页
Asia-Pacific Traditional Medicine
